MAGIC Act

United States116th CongressHR-4244House of Representatives
Updated: Sep 10, 2019

Summary

Market Access for Generic Insulin Competition or the MAGIC Act This bill provides a pathway for the Food and Drug Administration to approve chemically synthesized insulin or an analogue of chemically synthesized insulin as a generic drug under the abbreviated new drug application process.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  2. Introduced in House

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.